Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
This study demonstrated the heterogeneity of treatments after 1L PBC-containing therapy for patients with ES-SCLC, with no clear standard of care identified. In 3L, rwTTD/D, rwTTNT/D, and rwOS were short, demonstrating the substantial unmet need for novel treatments in this setting.
Authors
- Sudhir Unni (ORCID: https://orcid.org/0000-0002-0667-6277)
- Marian Eberl (ORCID: https://orcid.org/0000-0001-6584-3197)
- Mei Tang (ORCID: https://orcid.org/0000-0002-7294-0355)
- Boris Gorsh (ORCID: https://orcid.org/0000-0001-6977-0220)
- Friso Coerts (ORCID: https://orcid.org/0000-0002-6259-1251)
- K. Nathan Sankar (ORCID: https://orcid.org/0000-0001-8636-8479)
- Tara Herrmann
- Hoa H. Le (ORCID: https://orcid.org/0000-0001-6755-1331)
- S. Faisal Ahmed
Institutions
- Cedars-Sinai Medical Center (US)
- Daiichi Sankyo (Germany) (DE)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1007/s12325-025-03408-z
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Daiichi Sankyo Europe